Cell therapy products in the U.S. are estimated to be worth approximately $4.5 billion currently and expected to grow to over $30 billion in the next ten years. As market value increases litigation is bound to heat up....more
Allele v. Pfizer – The Basics. On April 23, 2021 Pfizer, Inc., BioNTechSE, and BioNTech US, Inc. (“Pfizer and BioNTech”) filed a joint reply supporting of their previously filed motion to dismiss a patent infringement...more
7/21/2021
/ 35 U.S.C. § 271(e)(1) ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Hatch-Waxman ,
Intellectual Property Protection ,
Inventions ,
Life Sciences ,
Motion to Dismiss ,
Patent Infringement ,
Patent Litigation ,
Patent Term Extensions ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Research Tools ,
Safe Harbors